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Abstract
OBJECTIVE: To study the efficacy and safety of
combined Traditional Chinese Medicine (TCM) ther-
apy based on nourishing marrow to improve intel-
lect and reinforcing Qi to activate bloodon mild to
moderate Alzheimer's disease (AD).
METHODS: Sixty-six patients with AD, whoseMi-
ni-Mental State Examination (MMSE) score were
from 10-24, were randomized equally into an inter-
vention group and a control group. The control
group was given Aricept (5 mg, once daily). The in-
tervention group was further divided into Yang-Qi
deficiency (n = 18) and of Yin-Qi deficiency (n = 15)
subgroups. Patients in the Yang-Qi deficiency
group were intravenously administered Shenfu in-
jection, 60 mL, and deproteinized calf blood injec-
tion (DCBI), 1.2 g, once daily. The Yin-Qi deficiency
group was given Shenmai injection, 60 mL, and DC-
BI, 1.2 g, once daily. Each course lasted 21 days.
RESULTS: Compared with the control group and
with pre-treatment in the same group, MMSE, clini-
cal dementia rating, and activities of daily living
scale scores in the intervention group were signifi-
cantly improved (all P < 0.05). These metrics mildly
improved in the control group compared with be-
fore treatment (P > 0.05). No adverse effects were
observed in any group during treatment.
CONCLUSION:We found that combined TCM thera-
py is effective and safe for managing mild to mod-
erate AD.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Alzheimer's disease (AD) is a progressive degenerative
disease of the nervous system, which manifests as de-
clined cognitive function, mental behavior, and ability
to complete the activities of daily life. The prevalence
of AD is increasing as the population ages, placing
aheavy burden on families and society. Aricept is effec-
tive in the treatment of AD by inhibiting the degrada-
tion of acetylcholine in the brain, which increases the
concentration of acetylcholine in the cerebral cortex.1
We aimed to use a combined Traditional Chinese Med-
icine (TCM) treatment, based on nourishing marrow
to improve intellect and reinforcing Qi to activate
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blood, to treat mild to moderate AD. We compared
this TCM treatment with that of conventional Aricept.
MATERIALS ANDMETHODS
Diagnosis criteria
AD was diagnosed according to the American Diagnos-
tic and Statistical Manualof Mental Disordersand the
standarddiagnosis criteria of the National Institute of
Neurological Disorders and Stroke.2
Inclusion and exclusion criteria
Patients were included if they: (a) met the diagnostic
criteria; (b) were ≥55 years old; (c) had a MMSE score
from 10-24; (d) were able to see, hear, speak to accom-
plish each measurement; (e) agreed to the treatment
and signed their informed consent. This treatment was
approvedby the Medical Ethics Committee of First Af-
filiatedHospital of Zhongshan University.
The exclusion criteria included: (a) dementia caused by
other disease, such as vascular disease, brain trauma, en-
cephalitis, Parkinson's disease and other problems; (b)
patients who received prior treatment for AD; (c) pa-
tients who had other severe cardiovascular, hepatic, or
renal disease.
Patient grouping
Sixty-six AD patients were treated in the Department
of Neurology or Traditional Chinese medicine (TCM)
of the First Affiliated Hospital of Sun Yet-sun Universi-
ty, from 2007 to 2013. Patients were randomized
equally into an intervention group and control group
using the software SPSS 12.0 (SPSS, Chicago, IL,
USA). The intervention group was further divided into
the Yang-Qi deficiency (n = 18) and Yin-Qi deficiency
subgroups (n = 15), as previously described.3 Study sub-
jects were blinded to treatments,while resultsevaluators
were unblinded.
There were no significant differences among groups in
terms of age, gender, disease course, pathogenic condi-
tions, including the mini-mental state examination
(MMSE) scores, clinical dementia rating (CDR)
scores,activities of daily living scale (ADL) scores, or
years of education before treatment (all P > 0.05)
(Table 1).
Treatment
Patients in the control group were orally administered
5 mg of Aricept (Eisai pharmaceutical [Suzhou] Co.,
Ltd.,batch No. H20050978, Suzhou, China) once a
night.Patients in the Yang-Qi deficiency subgroup were
intravenously administered Shenfu injection (Ya'an
999 Pharmaceutical Co., Ltd., Ya'an, China; batch No.
Z51020664), which is composed of Hongshen (Radix
Ginseng Rubra) and Fuzi (Radix Aconiti Lateralis Pre-
parata), 60 mL via intravenous drip, once daily. The
Yang-Qi deficiency subgroup was also given deprotein-
ized calf blood injection, (DCBI, Jinzhou Aohong
Pharmaceutical Co., Ltd., Jinzhou, China; batch No.
H20010762; one 10 mL ampoule contains 0.4 g) 1.2 g,
intravenous drip, once daily. The Yin-Qi deficiency
subgroup was intravenously administered 60 mL of
Shenmai injection (Ya'an 999 Pharmaceutical Co.,
Ltd., batch No. Z51021879), which is composed of
Hongshen (Radix Ginseng Rubra) and Maidong (Radix
Ophiopogonis Japonici) once daily, plus 1.2 g of DCBI
once daily via intravenous drip.The treatment course
for both groups was 21 days.
Observation indicators and methods
Before and after treatment, each AD patient was evalu-
ated with: (a) MMSE4 to assess cognitive function; (b)
CDR4to assess degree of dementia; and (c) ADL4 to as-
sess activities of daily life.
Safety evaluation
Before and after treatment, the following were assessed:
(a) neurological examination; (b) vital signs; (c) labora-
tory examination, including blood, urine, and stool
panels; liver and kidney function tests; and blood glu-
cose and electrolytes; and (d) electrocardiogram and
chest X-ray.
Statistical analysis
Statistical analyses were performed with SPSS (Chicago,
IL, USA). Data are presented as mean ± standard devia-
tion ( xˉ ± s). Measurement data were compared using
t-test. P < 0.05 is considered statistically significant.
RESULTS
Cognitive function
From before to after treatment, MMSE scores in-
creased from 16.8 ± 4.3 to 27.7 ± 2.0 in the inter-
vention group (P < 0.05), and 15.2 ± 4.7 to 17.7 ±
2.4 in the control group (P > 0.05). The MMSE
score increasedmore significantly in the intervention
group than that in the control group (P < 0.05) (Ta-
ble 2).
Dementia level score
After treatment, the CDR scores decreased significant-
ly in the intervention group (P < 0.05), while the con-
trol group scores decreased mildly compared to before
treatment (P > 0.05). The decrease in the CDR score
was significantly greater in the intervention group than
that in the control group (P < 0.05) (Table 2).
Self-care ability in daily living
After treatment, the ADL scores significantly decreased
in the intervention group (P < 0.05), while the control
group scores were decreased mildly compared with be-
fore treatment (P > 0.05). The decrease in the ADL
score was significantly greater in the intervention
group than that in the control group (P < 0.05) (Ta-
ble 2).
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In the intervention group, drugs were withdrawn after
3 weeks of treatment, and there was no noticeable
symptom rebounding after 12 weeks of follow-up. The
control group maintained administration of Aricept.
Adverse reactions
No abnormal changes were found in the laboratory ex-
amination in either group. No abnormal changes were
found in the neurologic examination, vital signs, elec-
trocardiogram, or chest X-ray in either group. During
treatment, four patients in the intervention group expe-
rienced mild dizziness, but symptoms improved after
slowing down the speed of medicine infusion. In the
control group, three patients suffered from excitation
and insomnia, but changing the time of Aricept admin-
istration from night to morning improved the symp-
toms. No adverse reactions that impacted treatment
were observed.
DISCUSSION
AD is a neurodegenerative disorder of the central ner-
vous system. The clinical manifestation of AD is
thought to be caused by acetylcholine dysfunction in
the neurons of the cerebral cortex. AD symptoms re-
sult from decreased choline acetyltransferase activity
and therefore reduced acetylcholine concentration in
the brain.5 Aricept is a specific inhibitor of acetylcholin-
esterase, and inhibition of acetylcholine degradation in
the central system has been shown to improve cogni-
tive dysfunction. While acetylcholinesterase inhibitors
can improve cognitive function in patients with AD af-
ter 4 weeks, it must be taken continuously to maintain
its effect. We found that Aricept did not improve the
manifestation of AD after 21 days, which is consistent
with other reports.4 However, the combined TCM in-
tervention group had significantly improved MMSE,
CDR, and ADL scores compared with before treat-
ment and compared with the control group (all P <
0.05).
According to TCM, the fundamental etiology and
pathogenesis of AD is Kidney deficiency. Congestion
and muddy phlegm are important factors for the onset
of AD. Yi Xue Xin Wu 6 stated that "intellect is based
on kidney. Kidney deficiency leads to mental retarda-
tion," and "insufficiency of kidney essence leads to
brain marrow dystrophy, and dementia." AD is consid-
ered to lead to stagnant blood and muddy phlegm ac-
cumulation because of the deficiency of Qi and blood,
and dysfunction of viscera. Ling Shu Ying Wei Sheng
Hui 7stated that"Qi and blood of the elderly is defi-
cient.Theirmuscles are withered and consumed, Qi-pas-
sages arestagnant, nutrient Qi is declined, and defense
Qi is subjugated inwardly." Therefore, AD treatment
should include the pathogenic factors of kidney defi-
ciency, marrow vacancy, and blood stagnancy because
of Qi deficiency. Moreover, treatment should focus on
invigorating the kidney to consolidate semen, nourish-
ing the cerebral marrow to improve intellect, and rein-
forcing Qi to activate blood.
When treating AD in TCM, reinforcing kidney is em-
phasized. TCM treatment aims to increase essence and
marrow to nourish the brain. DCBI has been shown to-
significantly improve damaged brain cells, and can pro-
vide protection and nutrition, and restore cerebral neu-
rons via multiple targets.8-12 These effects from DCBI
are similar to nourishing marrow to improve intellect
in TCM.
Notes: the control group was orally administered Aricept. The intervention group was further divided into the Yang-Qi deficiency
(n = 18) and Yin-Qi deficiency subgroups (n = 15). Patients in the Yang-Qi deficiency subgroup were intravenously administered
Shenfu injectionplus a deproteinized calf blood injection. The Yin-Qi deficiency subgroup was intravenously administered Shenmai in-
jection plus a deproteinized calf blood injection. MMSE: mini-mental state examination; CDR: clinical dementia rating; ADLS: activi-
ties of daily living scale.
Group
Intervention
Control
n
33
33
Male
(n)
20
18
Female
(n)
13
15
MMSE
16.8±4.3
15.2±4.7
CDR
1.5±0.4
1.6±0.5
ADLS
46.2±7.9
47.3±6.1
Educated
year
9.1±5.3
8.3±4.7
Age
(years)
67.9±13.3
69.2±15.7
Course of disease
(years)
3.9±2.9
3.7±3.1
Table 1 Alzheimer's patient information in both treatment groups ( xˉ ± s)
Group
Intervention
Control
n
33
33
MMSE
Pre-treatment
16.8±4.3
15.2±4.7
Post-treatment
27.7±2.0ab
17.7±2.4
CDR
Pre-treatment
1.5±0.4
1.6±0.5
Post-treatment
0.8±0.3ab
1.4±0.4
ADLS
Pre-treatment
46.2±7.9
47.3±6.1
Post-treatment
29.5±7.6ab
41.5±6.3
Table 2 Changes in rating scales of Alzheimer's patients before and after treatment ( xˉ ± s)
Notes: the control group was orally administered Aricept. The intervention group was further divided into the Yang-Qi deficiency (n = 18)
and Yin-Qi deficiency subgroups (n = 15). Patients in the Yang-Qi deficiency subgroup were intravenously administered Shenfu injection-
plus a deproteinized calf blood injection. The Yin-Qi deficiency subgroup was intravenously administered Shenmai injection plus a deprot-
einized calf blood injection.MMSE: mini-mental state examination; CDR: clinical dementia rating; ADLS: activities of daily living scale.
aP < 0.05, compared with the pre-treatment in the same group; bP < 0.05, compared with the control group after treatment.
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DCBI can activate aerobic metabolism, and increase
the production of ATP in the mitochondria, which in-
creases the use of oxygen in neurons. DCBI also con-
tains phosphoinositide oligosaccharides, which can
stop nitric oxide (NO) synthesis by inhibiting NO syn-
thase. Therefore, DCBI blocks the NO-mediated isch-
emic cascade and prevents cell damage.13 We found
that DCBI combined with Shenmai or Shenfu was
very effective for AD. After 21 days of treatment, the
MMSE, CDR, and ADL scores in the intervention
group were all improved (all P < 0.05). The combined
therapy may repair the neuronal damage that causes
AD at the molecular and cellular levels.
Hongshen (Radix Ginseng Rubra) is the main ingredi-
ent in the Shenmai and Shenfu injections. The main
bioactive compounds found in Hongshen (Radix Gin-
seng Rubra) are ginseng saponins, which have neuro-
trophic functions and can enhance brain energy metab-
olism. They also canreduce NO production, prevent
free radical damage, protect neurons, increase synaptic
neurotransmitter uptake, and significantly inhibit ace-
tylcholinesterase. Moreover, ginseng saponins can regu-
late immune function and enhance memory in the cen-
tral nervous system. Ginsenosides Rb1 and Rg1, which
are ginseng saponins, can increase the density of musca-
rinic acetylcholine receptors. By inhibiting the
cAMP-dependent phosphodiesterase in the hippocam-
pus of aged rats, ginseng saponins can also reduce the
concentration of intracellular synaptic calcium ions,
and resist excitatory amino acid neurotoxicity to pro-
tect nerve cells. Therefore, Hongshen (Radix Ginseng
Rubra) has possible anti-AD effects.14
In TCM, Hongshen (Radix Ginseng Rubra) nourishes
the brain and reinforces intelligence. It can also rein-
force Qi to activate and improve blood circulation,
which helps other drugs reach the lesions. Ben Cao Jing
Shu, a classic Chinese treatise for description of the
properties and functions of Traditional Chinese Medi-
cine,15 stated that "Hongshen (Radix Ginseng Rubra)
can tonify genuine Yang Qi of the five Zang-organs and
is effective in patients suffering from genuine Yang ex-
haustion and kidney Qi deficiency."
According to TCM theories, Qi deficiency is divided
into Yang-Qi deficiency and Yin-Qi deficiency.3 Pa-
tients with Yang-Qi deficiency often have cold limbs,
the need to urinate frequently at night, little desire to
talk, shortness of breath, devitalized essence-spirit, a
pale and fat tongue with scalloped edges, glossy white
or slimy white tongue fur, and a deep, fine, and weak
pulse or floating, large, and weak pulse. Patients with
Yin-Qi deficiency often have a pale white complexion,
lassitude, palpitation, reduced sleep, forgetfulness, vexa-
tion, a dry mouth, tinnitus, backache, limp knees, red
tongue with scanty fur, and a fine, string-like pulse.
Treatment based on syndrome differentiation results in
the best treatment effect.
Shenfu injection is prepared from Hongshen (Radix
Ginseng Rubra) and Fuzi (Radix Aconiti Lateralis Pre-
parata). Hongshen (Radix Ginseng Rubra) can tonify
Qi, prevent exhaustion, and nourish Qi to vitalize the
blood. Fuzi (Radix Aconiti Lateralis Preparata) can as-
sist Yang with pungent warmth and free the twelve
channels. The combination of the two medicines can
boost Qi, warm Yang, move blood, and free channels.
Shenfu injection contains ginsenosides, water-soluble
alkaloids, and many other biologically active compo-
nents. The injection can improve brain energy metabo-
lism by increasing cerebral blood flow and slowing
down the damage of cellular structures by preventing
intracellular calcium overload.16 Fuzi (Radix Aconiti
Lateralis Preparata) has glucocorticoid-like anti-inflam-
matory effects. Compounds found in the herb can di-
late brain arteries and improve brain hypoxia via an-
ti-coagulation and anti-platelet aggregation effects. The
drug can also restore brain neuron injury.17
Shengmai injection is prepared from Hongshen (Radix
Ginseng Rubra) and Maidong (Radix Ophiopogonis Ja-
ponici). Maidong (Radix Ophiopogonis Japonici) has a
slightly cold nature that nourishes Yin and boosts Qi.
Shengmai injection can boost Qi, nourish blood and
Yin, and vitalize liquids.18
The pattern type in TCM provides a basis for TCM
treatment and does not affect treatment efficacy evalua-
tions.3 Therefore, we did not distinguish or analyze ef-
fectiveness between the TCM pattern types.
Our TCM-based protocol aims to manage AD by nour-
ishing marrow to improve intellect and reinforcing Qi
to activate blood. DCBI combined with Shenfu or
Shenmai has definitive effects on improving the symp-
toms of mild to moderate AD in terms of cognitive
function, dementia, and self-care ability in daily living.
During treatment, no adverse effects that affected the
treatment were observed.
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